Fig 5. Endogenous TFII-I contributes to CMV promoter activity in human cells.

U2OS cells were transfected with a mixture of siRNAs targeting TFII-I (si TFII-I) or non-targeting control siRNAs (si ctrl). Twenty four hours later, the same cells were transfected again, this time with the CMVdel1 luciferase construct (A) or the β-galactosidase construct pcDNA3.1(-)/myc-His/LacZ (LacZ) (B). Cells were lysed 24 hours later. The graphs show the relative changes in luciferase activity or β-galactosidase activity, respectively, in three independent experiments (mean +/- standard deviation; * P<0.05, ** P<0.01). The representative results of Western blotting analysis illustrate the efficiency of TFII-I knock down in the presented experiments.